ANCA-ассоциированный быстропрогрессирующий гломерулонефрит


DOI: https://dx.doi.org/10.18565/nephrology.2018.3.72-87

Н.Ф. Фролова

ГБУЗ «Городская клиническая больница № 52» ДЗМ; Москва, Россия
АНЦА-ассоциированные гломерулонефриты (ГН) – группа заболеваний с поражением клубочков почки, в основе которых лежит некротизирующий васкулит, связанный с образованием антител к цитоплазме нейтрофилов. Клинической особенностью АНЦА-ГН является склонность к быстропрогрессирующему течению ГН со снижением скорости клубочковой фильтрации более чем на 50% в течение нескольких недель или месяцев. В статье представлен обзор литературы, посвященной эпидемиологии, классификации, этиологии и патофизиологии, клинике и лечению ANCA-ассоциированного быстропрогрессирующего ГН.
Ключевые слова: Быстропрогрессирующий гломерулонефрит, васкулит
Полный текст статьи доступен
в "Библиотеке Врача"

Литература

  1. Бекетова Т.В. АНЦА-ассоциированный системный васкулит. Нефрология. Национальное руководство краткое издание. М., 2014. С. 287–304.
  2. Бекетова Т.В. Гранулематоз с полиангиитом, патогенетически связанный с антинейтрофильными цитоплазматическими антителами: особенности клинического течения.Научно-практическая ревматолология. 2012;50(6):19–28.
  3. Бекетова Т.В. Современная классификация системных васкулитов. Терапевтический архив. 2014;5:92–98.
  4. Бекетова Т.В., Фролова Н.Ф., Столяревич Е.С., Волков М.Ю., Котенко О.Н., Александрова Е.Н. Проблемы диагностики и лечения АНЦА-ассоциированных системных васкулитов: в фокусе АНЦА-негативный PAUCI-иммунный гломерулонефрит. Научно-практическая ревматология. 2016;5(54):С.543–552.
  5. Бекетова Т.В. Перспективы применения Ритуксимаба при васкулитах, ассоциированных с антинейтрофильными цитоплазматическими антителами. Научно-практическая ревматология. 2010;4(1):80–90.
  6. Бирюкова Л.С., Столяревич Е.С., Кальянова Е.В., Фролов А.В., Тырин В.В., Артюхина Л.Ю., Фролова Н.Ф., Федорова Н.Д., Томилина Н.А. Опыт лечения быстропрогрессирующего гломеркулонефрита при АНЦА-Ассоциированом васкулите.Нефрология и диализ. 2013;15(4):306–307.
  7. Егорова Е.Т., Томилина Н.А., Бирюкова Л.С. Быстропрогрессирующий гломерулонефрит при АНЦА-ассоциированных васкулитах: течение, эффективность лечения, прогноз. 2007;9(3):228–239.
  8. Захарова Е.В. ANCA-ассоциированные и криоглобулинемические васкулиты диагностика и лечение. Нефрология и гемодиализ. 2005;1(7):6–25.
  9. Захарова Е.В., Яковлев В.Н., Виноградова О.В., Шейх Ж.В., Алексеев В.Г. АНЦА-ассоциированные васкулиты с поражением легких и почек: клинико-морфологическая характеристика, лечение, исходы. Клиническая медицина. 2013;7:38–43.
  10. Козловская Н.Л., Гордовская Н.Б., Коротчаева Ю.В.Нефрит, ассоциированный с антинейтрофильными цитоплазматическими антителами. Клинические рекомендации. Нефрология. М., 2016.
  11. Кривошеев О.Г. Поражение почек при васкулитах, ассоциированных с антителами к цитоплазме нейтрофилов (ANCA-васкулитах). Рациональная фармакотерапия в нефрологии. М., 2006:293–306.
  12. Мухин Н.А., Семенкова Е.Н., Кривошеев О.Г. и др. Применение ритуксимаба при тяжелых АНЦА-ассоциированных системных васкулитах. Клиническая нефрология. 2010;2:40–45.
  13. Мухин Н.А., Козловская Л.В., Насонов Е.Л. и др. Клиническое значение и патогенетические аспекты поражения почек, связанного с антителами к цитоплазме нейтрофилов. Вестник РАМН. 1995;5:34–9.
  14. Новиков П.И., Моисеев С.В., Буланов Н.М., Макаров Е.А. Современные подходы к терапии АНЦА-ассоциированных системных васкулитов. Клиническая Нефрология. 2014;1:42–49.
  15. Семенкова Е.Н., Бекетова Т.В., Коган Е.А. и др. Современные представления о микроскопическом полиартериите. Тер. арх. 1995;5:39–41.
  16. Томилина Н.А., Бирюкова Л.С., Егорова Е.Т., Суханов А.В., Столяревич Е.С., Купавцева О.А., Федорова Н.Д., Фролов А.В., Трушкин Р.Н., Куренкова Л.Г. Быстропрогрессирующий гломерулонефрит при АНЦА-ассоциированных васкулитах: течение, эффективность лечения, прогноз. Терапевтический архив. 2008;80(6):15–24.
  17. Фролова Н.Ф., Волгина Г.В., Бирюкова Л.С., Столяревич Е.С., Томилина Н.А. Клинико-морфологические корреляции и прогноз при разных гистоморфологических вариантах быстропрогрессирующего ANCA-ассоциированного гломерулонефрита. Лечебное дело. 2016;4:68–77.
  18. Фролова Н.Ф., Лосс К.Э., Подкорытова О.Л., ВетшеваМ.С., Волгина Г.В. и др. Новые аферезные технологии в лечении ANCA-ассоциированного васкулита. Неотложная медицина. 2016;33(4):40–44.
  19. Фролова Н., Бирюкова Л., Столяревич Е., Фролов А., Волгина Г.В., Томилина Н. Применение ритуксимаба при лечении ANCA-ассоциированного васкулита: опыт одного центра. Материалы IV конгресса ассоциации нефрологов новых независимых государств. 2016. С. 52–53.
  20. Шилов Е.М., Козловская Н.Л., Коротчаева Ю.В. Клинические рекомендации по диагностике и лечению быстропрогрессирующего гломерулонефрита (экстракапиллярного гломерулонефрита с полулуниями). Нефрология. 2015;19(6):73–82.
  21. Yoshihiro A., Eri M., Shoichi F., Midori H., Shinya K., Joichi U. еt al. Evidence-based clinical practice guidelines for rapidly progressive glomerulonephritis 2014. Clin. Exp. Nephrol. 2016;20.(3):322–41.
  22. Adu D., Pall A., Luqmani R.A., Richards N.T., Howie A.J., Emery P., et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM.1997;90:401–9.
  23. Basu N., Watts R., Bajemal J. et al. EULAR pointstoconsider in the development of classification and diagnosticcriteria in systemic vasculitis. Ann. Rheum.Dis. 2010;69(10):1744–1750.
  24. Beaudreuil S., Lasfargues G., Lauériere L., El Ghoul Z., Fourquet F., Longuet C., et al. Occupational exposure in ANCA-positive patients: A case-control study. Kidney Int. 2005;67:1961–6.
  25. Berden A.E., Ferrario F., Hagen E.C. et al. Histopathological classification of ANCA-associated glomerulonephritis. J. Am. Sos. Nephrol. 2010;21:1628–1636.
  26. Berden A.E., Nolan S.L., Morris H.L., et al. Anti-plasminogen antibodies compromise fibrinolysis and associate with renal histology in ANCA-associated vasculitis. J. Am. Soc. Nephrol. 2010;21:2169–2179.
  27. Birck R., Schmitt W.H., Kaelsch I.A., et al. Serial ANCA determinations for moni- toring disease activity in patients with ANCA-associated vasculitis: systematic review.Am. J. Kidney Dis. 2006;47:15–23.
  28. Birukova L., Stolyarevich E.C., Frolova N.F., et al. The long-term renal outcome in patients with ANCA-associated vasculitis, predictive value of kidney biopsy. Posters in ERA EDTA congress London. 2015;28(31):108 p.
  29. Bonaci-Nikolic B., Andrejevic S., Pavlovic M., et al. Prolonged infections associated with antineutrophil cytoplasmic antibodies specific to proteinase 3 and myeloperoxidase: diagnostic and therapeutic challenge. Clin. Rheumatol. 2010;29:893–904.
  30. Booth, A.D., Almond, M.K., Burns, A. et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am. J. Kidney Dis. 2003;41:776–784.
  31. Bjørneklett R., Sriskandarajah S., Bostad L. Clin J. Prognostic Value of Histologic Classification of ANCA-Associated Glomerulonephritis. Am. Soc. Nephrol. 2016;7(11–12):2159–2167. Epub 2016, Oct. 18.
  32. Cartin-Ceba R., Golbin J.M., Keogh K.A., et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): ten-year experience at a single center. Arthritis Rheum. 2012;64(11):3770–3778.
  33. Chang D.Y., Wu L.H., Liu G., Chen M., Kallenberg C.G., Zhao M.H. Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center. Nephrol. Dial. Transplant. 2012;27(6):2343–234.
  34. Chen Min M.D., Yu Feng M.D., Zhang Y., Zhao M.D. ANCA-associated vasculitides-advances in pathogenesis and treatment. Nat. Rev. Rheumatol. 2010;6:653–64.
  35. Chen М. Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Older Patients. PhD. Medicine. 2008;87(4):203–209. Doi: 10.1097/MD.0b013e31817c744b
  36. Chen M., Kallenberg С.G. The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun. Rev. 2010;9:A293–A298.
  37. Chen M., Kallenberg C.G., Zhao M.H. ANCA-negative pauci-immune crescentic glomerulonephritis. Nat. Rev. Nephrol. 2009;5(6):313–318.
  38. Xu J., Pan X.X., Shen P.Y., Li X., Ren H., Chen X.N., Ni L.Y., Zhang W., Chen N. Histopathological Classification and Renal Outcome in Patients with Antineutrophil Cytoplasmic Antibodies-associated Renal Vasculitis: A Study of 186 Patients and Metaanalysis. Rheumatol. 2017;44(3):304–313. Doi: 10.3899 jrheum.160866. Epub 2016, Dec. 15.
  39. Chow K., Wang A.Y., Mac-Moune L.F., Wong T.Y., Li P.K. Rapid recurrence of ANCA-negative pauci-immune vasculitis after cadaveric renal transplantation. Am. J. Kidney Dis. 2001;38:E3.
  40. Clean A., Savage C.O.S. The immunopathogenesis of vasculitis Revised International Chapel HiLL. Consensus Conference Nomenclature of Vasculitides Arthritis Rheum. 2013;65(I–II):117–130.
  41. Córdova-Sánchez B.M., Mejía-Vilet J.M., Luis E., et al. Clinical presentation and outcome prediction of clinical, serological, and histopathological classification schemes in ANCA-associated vasculitis with renal involvement. Clin. Rheumatol. Published. 2016. Doi 10.1007/s10067-016-3195-z.
  42. Corral-Gudino L., Borao-Cengotita-Bengoa M., Lerma-Marquez J.L., del Pino-Montes J. Differences in the incidence of microscopic polyangiitis and granulomatosis with polyangiitis (Wegener’s). J. Rheumatol. 2011;38:2494–2496.
  43. Craven A., Robson J., Ponte C., Grayson P.C., Suppiah R., et al. ACR/EULAR-endorsed study to develop Diagnostic and Сlas- sification Criteria for Vasculitis (DCVAS). Clin. Exp. Nephrol. 2013;17(5):619–621.
  44. Csernok E., Lamprecht P., Gross W.L. Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis. Curr. Opin. Rheumatol. 2010;22:43–48.
  45. Davenpor T.A. “False positive” perinuclear and cytoplasmic anti-neutrophil cytoplasmic antibody results leading to misdiagnosis of Wegener’s granulomatosis and/or microscopic polyarteritis. Clin.Nephrol.1992;37:124–130.
  46. Davies D.J., Moran J.E., Niall J.F., et al. Segmental necrotizing glomeruloneph-ritis with antineutrophil antibody: possible arbovirus aetiology? Br. Med. J. 1982;285:6342–606.
  47. Eisenberger U., Fakhouri F., Vanhille P., et al. ANCA-negative pauci-immune renal vasculitis: histology and outcome. Nephrol. Dial. Transplant. 2005;20(7):1392–1399.
  48. Ellis A. Natural history of Bright’s disease: clinical, histological and experimental observations. Lancet. 1942;1:1–7.
  49. Ellis C.L., Manno R.L., Havill J.P., Racusen L.C., Geetha D. Validation of the new classification of pauci-immune glomerulonephritis in a United States cohort and its correlation with renal outcome. BMC Nephrol. 2013;14:210 р.
  50. EUVAS (European Vasculitis Study Group). Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann. Intern. Med. 2009;150(10):670–80.
  51. Ewert B.H., Jennette J.C., Falk R.J. Antimyeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidn.Int. 1992;41(2–3):75–83.
  52. Ernst Е., Girndt M., Pliquett R.U. A case of granulomatosis with polyangiitis complicated by cyclophosphamide toxicity and opportunistic infections: choosing between Scylla and Charybdis. BMC Nephrology. 2014;15:284.
  53. Falk R.J., Hogan S., Carey T.S., Jennette J.C. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. Ann. Intern. Med. 1990;113(9):656–63.
  54. Falk R.J., Jennette J.C. ANCA disease: Where is this field heading? J. Am. Soc. Nephrol. 2010;21:745–52.
  55. Falk R.J., Jennette J.C. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N. Engl. J. Med. 1988;318:1651–1657.
  56. Falk R.J., Terrell R.S., Charles L.A., et al. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in itro. Proc. Natl. Acad. Sci. 1990;87(11):4115–9.
  57. Fauci A.S., Wolff S.M. Wegener’s granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore).1973;52(6):535–61.
  58. Ferrario F., Vanzati A., Pagni F. Pathology of ANCA-associated vasculitis. Clinical and Experimental Nephrology. 2013;17(5):652–658.
  59. Finkielman J.D., Lee A.S., Hummel A.M., et al. ANCA are detectable in nearly all patients with active severe Wegener s granulomatosis. Am. J. Med. 2007;120(7):643.е9-643.е14.
  60. Flossmann O., Berden A., de Groot K., et al. European Vasculitis Study Group. Long-term patient survival in ANCA-associated vasculitis. Ann.Rheum.Dis 2011;70(3):488–494.
  61. Ford S.L., Polkinghorne K.R., Longano A., et al. Histopathologic and clinical predictors of kidney outcomes in ANCA-associated vasculitis.American Journal of Kidney Diseases. 2014;63(2):227–235.
  62. Franssen C.F., Stegeman C.A., Kallenberg C.G., et al . Antiproteinase 3-and antimyeloperoxidase-associated vasculitis. Kidney Int. 2000;57:2195–2206.
  63. Fujimoto S., Watts R., Kobayashi S., et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the UK. Rheumatology. 2011;50:1916–1920.
  64. Furuta S., Jayne D.R. Antineutrophil cytoplasm antibody-associated vasculitis: recent developments. Kidney Int. 2013;84:244–249.
  65. Geffriaud- Ricouard C., Noël L.H., Chauveau D., Houhou S., Grünfeld J.P., Lesavre P. Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients.Clin.Nephrol. 1993;39:125–136.
  66. Gibson A., Stamp L.K., Chapman P.T., O’Donnell J.L. The epidemiology of Wegener’s granulomatosis and microscopic polyangiitis in a Southern Hemisphere region. Rheumatology (Oxford). 2006;45:624–628.
  67. Gopaluni S. Clinical Trials in Vasculitis/Current Treatment Options in Rheumatology. 2016;2(2):161–177.
  68. Goldschmeding R., Tervaert J.W., Gans R.O., еt al. Different immunological specificities and disease associations of c-ANCA and p-ANCA. Neth. J. Med. 1990;36:114–116.
  69. González-Gay M.A., Garcia-Porrua C., Guerrero J., Rodriguez-Ledo P., Llorca J. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis. Rheum. 2003;49:388–393.
  70. Gou S.J., Yuan J., Chen M., Yu F., Zhao M.H. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2013;83:129–37.
  71. De Groot K., Adu D., Savage C.O. The value of pulse cyclophosphamide in ANCA. Vasculitis: meta-analysis and critical review. Nephrol. Dial. Transplant. 2001;16:2018–27.
  72. Guerry M.J., Brogan P., Bruce I.N., et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2012;51(4):634–643.
  73. Guillevin L. Treatment of severe and/or refractory ANCA-associated vasculitis. Curr. Rheumatol. Rep. 2014;16(8):430.
  74. Guillevin L., Cordier J.F., Lhote F., Cohen P., Jarrousse B., Royer I., et al. Prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis. Rheum. 1997;40:2187–98.
  75. Hall J.B., Wadham B.M., Wood C.J., et al. Vasculitis and glomerulonephritis: a subgroup with an antineutrophil cytoplasmic antibody. Aust. NZJ Med. 1984;14:277–278.
  76. Hao J., Wang C., Gou S.J., et al. The association between anti-plasminogen antibodies and disease activity in ANCA-associated vasculitis. Rheumatology (Oxford). 2014;53:300–306.
  77. Haubitz M., Frei U., Rother U., Brunkhorst R., Koch K.M. Cyclophosphamide pulse therapy in Wegener’s granulomatosis. Nephrol. Dial. Transplant. 1991;6:531–5.
  78. Harper L., Morgan M.D., Walsh M., et аl. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: Long- term follow-up. Ann. Rheum. Dis. 2012;71:955–960.
  79. Harada T. ANCA-negative pauci-immune crescentic glomerulonephritis complicated with recurrent massive gastrointestinal hemorrhage. Clin. Exp. Nephrol. 2005;9:174–178.
  80. Hedger N., Stevens J., Drey N., Walker S., Roderick P. Incidence and outcome of pauci-immune rapidly progressive glomerulonephritis in Wessex, UK: a 10-year retrospective study. Nephrol. Dial. Transplant. 2000;15:1593–1599.
  81. Hilhorst M., Wilde B., van Breda V.P., et al. Limburg Renal Registry. Estimating renal survivalusing the ANCA-associated GN classification. J. Am. Soc. Nephrol. 2013;24:1371–75.
  82. Hilhorst M., Winckers K., Wilde B., et al. Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable. J. Rheumatol. 2013;40:2042–2046.
  83. Hiemstra T., Walsh M., Schmitt W., Jayne D. Randomised controlled trial of mycophenolate mofetil versus azathioprine for maintenance therapy in ANCA-Associated vasculitis (IMPROVE).1–4th Nov. American. Society of Nephrology. 2009:SA-FC331A.
  84. Holle J.U., Hermann K., Gross W.L., Csernok E. Comparative analysis of different commercial ELISA systems for detection of anti-neutrophil cytoplasm antibodies in ANCA-associated vasculitides. Clin. Exp. Rheumatol. 2012;30(70):66–9.
  85. Homeister J.W., Jennette J.C., Falk R.J. Immunologic mechanisms of vasculitis. Seldin and Giebisch’s The Kidney. Amsterdam: Elsevier. 2013:2817–2846
  86. Hoffman G.S., Kerr G.S., Leavitt R.Y., et al. Wegener granulomatosis: an analysis of 158 patients. Ann. Intern. Med. 1992;116(6):488–498.
  87. Hu W., Liu C., Xie H., Chen H., Liu Z., Li L. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol. Dial. Transplant. 2008;23:1307–1312.
  88. Hung P.H. Poor renal outcome of antineutrophil cytoplasmic antibody negative pauci-immune glomerulonephritis in Taiwanese. J. Formos. Med. Assoc. 2006;105:804–812.
  89. Iwakiri T., Fujimoto S., Kitagawa K., Furuichi K., et al. Validation of a newly proposed histopathological classification in Japanese patients with anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. BMC Nephrology. 2013;14:125–133.
  90. Jayne D. The clinical presentation and treatment of renal vasculitis. Reumatology and the Kidney. 2013:163–180. Doi :10.1093/med/9780199579655.003.0064
  91. Jayne D.R. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J. Am. Soc. Nephrol. 2007;18:2180–2188.
  92. Jayne D., Pusey C. European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 2003;349(1):36–44.
  93. Jennette C.J., Falk R.J., Mc Gregor J.G. Comprehensive Clinical Nephrology 5th Edition. Renal and systemic valculitis. 2015.1320 р.
  94. Jennette J.C. Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis & Rheumatism. 2013;65(1):11.
  95. Jennette J.C. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37(2):187–92.
  96. Jennette J.C., Falk R.J. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat. Rev. Rheumatol. 2014;10:463–73.
  97. Jennette J.C., Hoidal J.H., Falk R.J. Specificity ofanti-neutrophil cytoplasmic autoantibodiesfor proteinase 3. Blood. 1990;75:2263–2264.
  98. Jennette J.C. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003;63(3):1164–77.
  99. Jones R.B., Furuta S., Tervaert J.W, et al. European Vasculitis Society (EUVAS). Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann. Rheum. Dis. 2015;74(6):1178–1182.
  100. Jones R.B., Tervaert J.W., Hauser T., et al. Rituximab versus cyclophosphamide in ANCA-as-sociated renal vasculitis. N. Engl. J. Med. 2010;363:211–220.
  101. Jha V. Renal and systemic vasculitis. Comprehensive Clinical Nephrology. St. Louis, MO: Saunders. 2010. 292–307 p.
  102. Kain R., Exner M., Brandes R., Ziebermayr R., Cunningham D., et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis.Nat. Med. 2008;14:1088–1096.
  103. Kain R. What is the evidence for antibodies to LAMP-2 in the pathogenesis of ANCA associated small vessel vasculitis? Curr. Opin. Rheumatol. 2013;25:26–34.
  104. Kain R., Tadema H., Mc Kinnas E.F. High prevalence of autoantibodies to HLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis. J. Am. Soc. Nephrol. 2012;23:556–566.
  105. Kallenberg C.G., Heeringa P. Complement is crucial in the pathogenesis of ANCA-associated vasculitis. Kidney Int. 2013;83:16–8.
  106. Kallenberg C.G. Pathogenesis and treatment of ANCA-associated vasculitides. Clin. Exp. Rheumatol. 2015;33:11–14.
  107. Kambham N. Crescentic glomerulonephritis: an update on pauci-immune and anti-GBM diseases.Adv. Anat. Pathol. 2012;19(2):111–124.
  108. Kanda T., Tanio H., Wu C., Nishihara H., Nogaki F., Ono T. Churg-Strauss syndrome with severe granulomatous angiitis and crescentic glomerulonephritis, which developed during therapy with a leukotriene receptor antagonist. Clinical and Experimental Nephrology. 2010;14(6):602–607.
  109. KDIGO. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int. Suppl. 2012;2:139–274.
  110. KDIGO. Clinical Practice Guideline for Glomerulonephritis. Kidney International supplements. Nephrology and dialysis. 2014.127–136 р.
  111. Kessenbrock K., Krumbholz M., Schönermarck U., et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat. Med. 2009;15:623–625.
  112. Koldingsnes W. Epidemiology of Wegener’s granulomatosis in northern Norway. Arthritis Rheum. 2000;43:2481–2487.
  113. Lamprecht P., Wieczorek S., Epplen J.T., Ambrosch P., Kallenberg C.G.M. Granuloma formation in ANCA-associated vasculitides. APMIS. 2009;117(127):32–36.
  114. Lee S, Hayashi H., Maeda M. et al. Environmental factors producing autoimmune dysregulation – chronic activation of T cells caused by silica exposure. 2012;217:743–748.
  115. Levy J.B., Hammad T., Coulthart А., Dougan T., Pusey C.D. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney International. 2004;66(4):1535–1540.
  116. Lie J. Vasculitis, to 1815 to1 991. Classification and diagnostic specificity. J. Rheumatol. 1991;19:83–89.
  117. Little M.A., Pusey C.D. Glomerulonephritis due to antineutrophil cytoplasmic antibodiy- associated vasculitis: An update on approaches to management. Nephrology. 2005;10:368–76.
  118. Lyons P.A., Rayner T.F., Trivedi S., Holle J.U., Watts R.A. et al. Genetically distinct subsets within ANCA-associated vasculitis. N. Engl. J. Med. 2012;367:214–223.
  119. Markiewski M.M. Complement and coagulation: strangers or partners in crime?Trends Immunol.2007;28:184–192.
  120. Mahr A., Moosig F., Neumann T., Szczeklik W., Taille C., Vaglio A., et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management. Current opinion in rheumatology. 2014;26:16–23.
  121. Manno L. Older patients with ANCA-associated vasculitis and dialysis dependent renal failure: are trospective study. BMC Nephrology. 2015;16:88.
  122. Millet A., Pederzoli-Ribeil M., Guillevin L., Witko-Sarsat V., Mouthon L. Antineutrophil cytoplasmic antibody-associated vasculitides. Is it time to split up the group? Ann. Rheum. Dis. 2013;72(8):1273–79.
  123. Minz R.W., Chhabra S., Joshi K., Rani L., Sharma N., Sakhuja V., et al. Renal histology in pauci-immune rapidly progressive glomerulonephritis: 8-year retrospective study. Indian J. Pathol. Microbiol. 2012;55:28–32.
  124. Mohammad A.J., Jacobsson L.T., Westman K.W., Sturfelt G., Segelmark M. Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology.2009;48:1560–5.
  125. Mohammad A.J., Jacobsson L.T., Mahr A.D., Sturfelt G., Segelmark M. Prevalence of Wegener’s granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg–Strauss syndrome within a defined population in southern Sweden. Rheumatology. 2007;46:1329–1337.
  126. Moran S., Little M.A. Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis. Curr. Opin. Rheumatol. 2014;26:37–41.
  127. Mukhtyar C., Flossmann O., Hellmich B. et al. European Vasculitis Study Group (EUVAS) (2008). Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann. Rheum. Dis. 2008;67(7):1004–10.
  128. Muso E. Evaluation of the newly proposed simplified histological classification in Japanese cohorts of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in comparison with other Asian and European cohorts. Clin. Exp. Nephrol. 2013;17(5):659–62.
  129. Moroni G., Binda V., Leoni A., Raffiotta F., Quaglini S., Banfi G., Messa P. Clin. Exp Rheumatol.Predictors of renal survival in ANCA-associated vasculitis. Validation of a histopatological classification schema and review of the literature. 2015;33(2,89):56–63.
  130. Nachman P.H., Denu-Ciocca C.J. Vasculitides. In: Lerma E.V., Bern J.S., Nissenson A.R., editors. Current Diagnosis and Treatment: Nephrology and Hypertension. New York. 2008. 265–275 р.
  131. Nakazawa D., Tomaru U., Suzuki A., et al. Abnormal conformation and impaired degradation of propylthiouracil-induced neutrophil extracellular traps: implications of disordered neutrophil extracellular traps in a rat model of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64:3779–3787.
  132. National Kidney Disease Education Program. Estimating GFR. http://nkdep.nih.gov/lab-evaluation/gfr/estimating.shtml. Accessed October 8, 2013. http://nephron.com/epi_equation.
  133. Nohr E., Girard L., James M., Benediktsson H. Validation of a histopathologic classification scheme for antineutrophil cytoplasmic antibody-associated glomerulonephritis. Human Pathology. 2014;45:(7):1423–1429.
  134. Ntatsaki E., Carruthers D., Chakravarty K., et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology.201;53:2306–2309.
  135. Ntatsaki E., Watts R.A., Scott D.G. Epidemiology of ANCA-associated vasculitis. Rheum. Dis. Clin. North. Am. 2010;36:447–461.
  136. O’Donnell J.L., Stevanovic V.R., Frampton C., Stamp L.K., Chapman P.T. Wegener’s granulomatosis in New Zealand: evidence for a latitude-dependent incidence gradient. Intern Med J. 2007;37:242–246.
  137. Ormerod A.S., Cook M.C. Epidemiology of primary systemic vasculitis in the Australian Capital Territory and south-eastern New South Wales. Intern. Med. J. 2008;38:816–823.
  138. Ozaki S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergol Int. 2007;56:87–96.
  139. Passen P., Tervaert J.W., Heeringa P. Mechanisms of vasculitis: How Pauci-Immune is ANCA-Associated renal Vasculitis. Exp. Nephrol. 2007;105:e10–e16.
  140. Pagnoux C. Churg-Strauss syndrome: evolving concepts. Discov. Med. 2010;9:243–52.
  141. Pendergraft W.F. Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Curr. Opin. Rheumatol. 2014;26:42–49.
  142. Peschel A., Basu N., Benharkou A., et al. Autoantibodies to h LAMP-2 in ANCA-negative pauci-immune focal necrotizing GN. J. Am. Soc. Nephrol. 2014;25:455–463.
  143. Popa E.R., Stegeman C.A., Kallenberg C.G., Tervaert J.W. Staphylococcus aureus and Wegener’s granulomatosis. Arthritis Res. 2002;4:77–79.
  144. Popa E.R., Tervaert J.W.C. The relation between Staphylococcus aureus and Wegener’s granulomatosis: current knowledge and future directions. Intern Med. 2003;42:771–780.
  145. Quintana L.F., Peréz N.S., Sousa E., Lida M.R., Meryl H. Griffiths., Manel Solé., David J. ANCA serotype and histopathological classification for the prediction of renal outcome in ANCA-associated glomerulonephritis. Nephrol. Dial. Transplant. 2014;29(9):1764–1769.
  146. Rao D.A., Wei K., Merola J.F., O’Brien W.R., Takvorian S.U., Dellaripa P.F., Schur P.H. Myeloperoxidase-antineutrophil Cytoplasmic Antibodies (MPO-ANCA) and Proteinase 3-ANCA without Immunofluorescent ANCA Found by Routine Clinical Testing. J. Rheumatol. 2015;42(5):847–852.
  147. Rao J.K., Allen N.B., Pincus T. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann. Intern. Med. 1998;1(129):345–52.
  148. Rees A.J., Cameron J.S. Crescentic glomerulonephritis. Oxford Textbook of Clinical Nephrology. 1st ed. Oxford: Oxford University Press. 1992. 418–38 р .
  149. Rihova Z., Maixnerova D., Jancova E., et al. Silica and asbestos exposure in ANCA-associated vasculitis with pulmonary involvement. Renal Failure. 2005;27(5):605–608.
  150. Rihova Z., Jancova E., Merta M., Rysava R., Reiterova J., Zabka J., Tesar V. Long-term outcome of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis with renal involvement. Kidney Blood Press. Res. 2005;28:144–152.
  151. Robson J., Doll H., Suppiah R., et al. Damage in the ANCA-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. Ann. Rheum. Dis. 2013;74:177–184.
  152. Rocha-Parise M., Santos L.M, Damoiseaux J.G., et al. Lymphocyte activation in silica-exposed workers. Int. J. Hyg. Environ Health. 2014;217:586–591.
  153. Roth A.J., Brown M.C., Smith R.N., et al. Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J. Am. Soc. Nephrol. 2012;23:545–555.
  154. Sanders J.S., Huitma M.G., Kallenberg C.G., et al. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology (Oxford) 2006;45:724–729.
  155. Sampathkumar K. ANCA negative pauci-immune glomerulonephritis with systemic involvement. Indian J. Nephrol. 2010;20(1):43–47.
  156. Savage C.O., Pottinger B.E., Gaskin G., et al. Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells.Am J. Pathol. 1992;141:335–342.
  157. Schilder A.M. Wegener’s granulomatosis vasculitis and granuloma. Autoimmun. Rev. 2010;9(7):483–7.
  158. Schönermarck U., Gross W.L., de Groot K. Treatment of ANCA-associated vasculitis. Nat. Rev. Nephrol.2014;10:25–36.
  159. Scott D.G., Watts R.A. Epidemiology and clinical features of systemic vasculitis. Clin. Exp. Nephrol. 2013;17:607–610.
  160. Seo P., Specks U., Keogh K.A. Efficacy of rituximab in limited Wegener’s granulomatosis with refractory granulomatous manifestations. J. Rheumatol. 2008;35(10):2017–23.
  161. Seo P., Stone J.H. The antineutrophil cytoplasmic antibody-associated vasculitides. Am. J. Med. 2004;117(1):39–50.
  162. Shah S., Havill J., Rahman M.H., Geetha D.A. historical study of American patients with anti-neutrophil cytoplasmic antibody negative pauci-immune glomerulonephritis. Clin. Rheumatol. 2016;35(4):953–960.
  163. Sharma A., Nada R., Naidu G.S., et al. Pauci-immune glomerulonephritis: does negativity of antineutrophilic cytoplasmic antibodies matters? Int. J. Rheum. Dis. 2016;19(1):74–81.
  164. Silva de Souza A.W. Autoantibodies in systemic vasculitis. Front Immunol. 2015;6:184.
  165. Silva S.V., Ferreira J.P., Carvalho S., et al. Antineutrophil cytoplasmatic antibody positive systemic vasculitis in a patient treated with propylthiouracil. Acta. Reumatol. Port. 2013;38:302–305.
  166. Sinico R.A., Di Toma L., Maggiors U. et al. Renal involvement in Churg-Straus syndrome.Am. J. Kidney Dis. 2006;47:770–779.
  167. Shah S., Geetha D. Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis. 7August. 2015;4:173–183.
  168. Smith R.M., Jones R.B., Guerry M.J., et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis. Rheum. 2012;64(11):3760–3769.
  169. Stegeman C.A., Tervaert J.W., Sluiter W.J., Manson W.L., de Jong P.E., Kallenberg C.G. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann. Intern. Med. 1994;120:12–17.
  170. Stone J.H., Merkel P.A., Spiera R., et al. RAVE-ITN Research Group: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 2010;363:221–232.
  171. Shah S., Hruskova Z., Segelmark M., et al. Treatment of Severe Renal Disease in ANCA Positive and Negative Small Vessel Vasculitis with Rituximab. Am. J. Nephrol. 2015;41:296–301.
  172. Shah S., Geetha D. Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis. 2015;4:173–183.
  173. Suneja M., Baiswar S., Vogelgesang S.A. Hydralazine associated pauci-immune glomerulonephritis. J. Clin. Rheumatol. 2014;20(2):99–102.
  174. Suppiah R. A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology (Oxford). 2011;50:899–905.
  175. Suzuki K., Nagao T., Itabashi M., et al. A novel autoantibody against moesin in the serum of patients with MPO-ANCA-associated vasculitis. Nephrol. Dial.Transplant. 2013;29:1168–1177.
  176. Syed R., Rehman A., Valecha G., et al. Pauci-immune crescentic glomerulonephritis: an ANCA-associated vasculitis. Biomed Res Int. 2015. 402826. Doi: 0.1155/2015/402826.
  177. Tan C.D., Smith A., Rodriguez E.R. Systemic necrotizing vasculitis induced by isoniazid. Cardiovasc. Pathol. 2014;23:181–182.
  178. Taylor S.R., Salama A.D., Joshi L., Pusey C.D., Lightman S.L. Rituximab is effective in the treatment of refractory ophthalmic Wegener’s granulomatosis. Arthritis Rheum. 2009;60(5):1540–1547.
  179. Tarzi R.M. Vasculitis: risks and rewards of treating elderly patients with vasculitis. Nat. Rev. Nephrol. 2011;7:253–255.
  180. Ten Holder S.M., Joy M.S., Falk R.J. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann. Pharmacother. 2002;36:130–147.
  181. Tervaert J.W., Damoiseaux J. Fifty years of antineutrophil cytoplasmic antibodies (ANCA) testing: do we need to revise the international consensus statement on testing and reporting on ANCA? APMIS. 2009;117(127):55–59.
  182. Tesar V., Hruskova Z. ANCA-associated Renal Vasculatis – an update Contrib. Nephrol., Basel Karger. 2013;181:216–228.
  183. Tian C., Kosoy R., Nassir R., et al. European population genetic substructure: further definition of ancestry informative markers for distinguishing among diverse European ethnic groups. Mol. Med. 2009;15:371–383.
  184. Van Daalen E., Ferrario F., Noël L.H., Waldherr R., Hagen E.C., Bruijn J.A., Bajema I.M. Twenty-five years of RENHIS: a history of histopathological studies within EUVAS. Nephrol. Dial. Transplant.2015;30:31–36.
  185. Villacorta J., Diaz-Crespo F., Acevedo M., et al. Antineutrophil cytoplasmic antibody negative pauci-immune extracapillary glomerulonephritis. Nephrology (Carlton). 2016;21(4):301–7.
  186. Wang, F., Min Chen М., ZhaoМ-Н. Neutrophil degranulation in antineutrophil cytoplasmic antibodies-negative pauci-immune crescentic glomerulonephritis. J. Nephrol. 2009.
  187. Watts R., Scott D. Vasculitis and related rashes. ABC of rheumatology, 4th Ed. by A. Adebajo. Blackwell. 2010;23:148–155.
  188. Watnick S., Dirkx T. Kidney disease in Current Medical Diagnosis & Treatment 2015, M. A. Papadakis, S. J. McPhee, and M. W. Rabow, Eds., McGraw-Hill, New York, NY, USA. 2014.
  189. Watts R.А. Vasculitis in Clinical Practice. Springer. 2010. Р. 198.
  190. Watts R.A., Lane S.E., Ben-tham G., Scott D.G. Epidemiology of systemic vasculitis – a 10 year study/Arthritis Rheum. 2000. 43. Р. 4. 22–427.
  191. Watts R.A., Mooney J., Skinner J., Scott D.G., Macgregor A.J. The contrasting epidemiology of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis. Rheumatology (Oxford). 2012. 51. 5. Р. 926–931.
  192. Watts R.A., Gonzalez-Gay M.A., Lane S.E., Garcia-Porrua C., Bentham G., Scott D.G. Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe. Ann. Rheum. Dis. 2001;60:170–172.
  193. Watts R.A., Lane S.E., Bentham G., Scott D.G. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum. 2000;43:414–419.
  194. Watts R.A., MacGregor A.J., Mackie S.L. HLA allele variation as a potential explanation for the geographical distribution of granulomatosis with polyangiitis. Rheumatol-ogy (Oxford). 2015;54:359–362.
  195. Wen Y.K., Chen M L. Transformation from tubulointerstitial nephritis to crescentic glomerulonephritis: an unusual presentation of ANCA-associated renal vasculitis. Ren Fail. 2006;28:189–191.
  196. Weyand C.M., Goronzy J.J., , Weyand C.M. Medium-and large-vessel vasculitis. N. Engl. J. Med. 2003;349:160–169.
  197. Weiner M., Goh S.M., Mohammad A.J., et al. Outcome and treatment of elderly patients with ANCA-associated vasculitis. Clin. J. Am. Soc. Nephrol. 2015;10:1128–1135.
  198. Wiesner O., Russell K.A., Lee A.S. et al. Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis. Rheum. 2004;50:2954–2965.
  199. Wijngaarden R.A., van Rijn L., Hagen E.C., Watts R.A., et al. Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody associated vasculitis: the cause is hidden, but the result is known. J. Clin. Am. Soc. Nephrol. 2008;3:237–252.
  200. Wilde B., Рaassen P., Witzke O., Tervaert J. New pathophysiological insights and treatment of ANCA associated vasculitis. Kidney International. 2011;59:599–612.
  201. Witko-Sarsat V.A., Lesavre P., Lopez S., et al. large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis. JASN. 1999;10(6):1224–1233.
  202. Woude F J., Rasmussen N., Lobatto S., Wiik A., Permin H., van Es L.A., et al. Autoantibodies against neutrophils and monocytes: Tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet. 1985;1:425–429.
  203. Wolff S.M., Fauci A.S., Horn R.G., Dale D.C. Wegener's granulomatosis. Ann. Intern. Med. 1974;81(4):513–525.
  204. Xiao Н., Hu Р., Falk R.J., Jennette J.С. Overview of the Pathogenesis of ANCA-Associated Vasculitis. Kidney Dis. 2015;1:205–215.
  205. Xu P., Lin S., Wei L., et al. Antineutrophil cytoplasmic antibody-associated vasculitis associated with Epstein-Barr virus infection: a case report and review of the iterature. XInfection. 2014;42:591–594.
  206. Zand L., Specks U., Sethi S., Fervenza F.C. Treatment of ANCA-associated vasculitis: new therapies and a look at old entities. Adv. Chronic. Kidney Dis. 2014;2:182–193.


Об авторах / Для корреспонденции

Фролова Н.М. – к.м.н., зав. 2-м нефрологическим отделением, врач-нефролог ГБУЗ «ГКБ №52 ДЗМ»; Москва, Россия.

К содержанию номера

Бионика Медиа